Cargando…
All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy
Autor principal: | Kudo, Masatoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603619/ https://www.ncbi.nlm.nih.gov/pubmed/37901769 http://dx.doi.org/10.1159/000533493 |
Ejemplares similares
-
Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy
por: Kudo, Masatoshi
Publicado: (2023) -
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
por: Kudo, Masatoshi
Publicado: (2023) -
Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure
por: Farsad, Khashayar, et al.
Publicado: (2020) -
Locoregional therapies for the treatment of locally advanced hepatocellular carcinoma
por: da Motta-Leal-Filho, Joaquim Maurício
Publicado: (2021) -
Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma
por: Chami, Perla, et al.
Publicado: (2023)